Honasa Consumer Ltd

Honasa Consumer Ltd announced a favorable rectification order in arbitration proceedings against RSMM General Trading LLC. Following an initial award, the company applied to rectify computational and clerical errors. The Arbitral Tribunal allowed the application, increasing the loss of profits award from AED 4.34 million to AED 7.32 million and correcting substitution costs. The revised award also includes a direction for RSM to pay damages related to any Dubai court decisions against Honasa concerning the distributor agreement. The final amended award directs RSM to pay Honasa Consumer a total of AED 9,918,514 (approximately INR 25.54 crore), with post-award interest applicable if unpaid within 30 days. RSM is also liable for damages equivalent to any amounts recovered against Honasa in related Dubai court proceedings.

Honasa Consumer Ltd has announced the closure of its trading window for equity shares. This closure will be effective from July 1, 2026, and will extend for 48 hours after the submission of unaudited standalone and consolidated financial results for the quarter ending June 30, 2026. The measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The disclosure will also be available on the company's website.

Honasa Consumer Limited has acquired a 58% majority stake in Fluence Pharma, a science-backed nutraceuticals company, marking its strategic entry into the high-growth nutraceuticals market. This move aims to leverage Fluence Pharma's patented Cyclical Nutrition Therapy (CNT) and dermatologist network to build a B2C nutrition portfolio under a new subsidiary, Honasa Health Private Limited. Fluence Pharma reported approximately ₹40 Crore revenue and over 20% EBITDA margin in FY26. The acquisition aligns with Honasa's vision of offering holistic, 'inside-out' beauty solutions and diversifying its growth engine.

Honasa Consumer Ltd's board has approved the acquisition of a 58% majority stake in Fluence Pharma Private Limited for an enterprise value of approximately ₹135 Crores. Fluence Pharma specializes in condition-specific OTC supplements under brands like 'Hair Fact, Skin Fact, and Pro Fact', utilizing a patented Cyclical Nutrition Therapy. The company also plans to acquire the remaining 42% stake in tranches over 5-7 years. Additionally, Honasa Consumer will incorporate a wholly owned subsidiary, 'Honasa Health Private Limited', to manage its nutraceuticals B2C operations. This move signifies Honasa's entry into the growing nutraceuticals market, leveraging Fluence Pharma's established presence and science-led approach.

Honasa Consumer Ltd has revised its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, as approved by the Board of Directors on May 21, 2026. This revision is in compliance with Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The updated code, effective from May 21, 2026, is available on the company's website.

Honasa Consumer Ltd's board approved audited financial results for FY26, recommending a final dividend of ₹3 per share. Subramaniam Somasundaram was re-appointed as an Independent Director for a second term. BDO India Services Private Limited was appointed as Internal Auditors for FY27. Several officials were designated as Senior Management Personnel, including Vipul Maheshwari, Nishchay Bahl, and Nilesh Kotalwar.

Honasa Consumer Ltd's board re-appointed Mr. Subramaniam Somasundaram as an Independent Director for a second term of five years, effective from February 11, 2027, to February 10, 2032, subject to shareholder approval. The board also approved a maiden final dividend of ₹3 per equity share (30% of face value of ₹10 each) for FY26, pending shareholder approval at the AGM. Additionally, BDO India Services Private Limited was appointed as Internal Auditors for FY27, and senior management personnel were designated.

Honasa Consumer Ltd's board, in its meeting on May 21, 2026, recommended a maiden final dividend of ₹3 per equity share (30% of face value of ₹10 each) for the financial year 2025-26, subject to shareholder approval at the AGM. The dividend, if declared, will be paid within 30 days from the AGM date. The board also approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Additionally, the board approved the re-appointment of Mr. Subramaniam Somasundaram as an Independent Director and the appointment of BDO India Services Private Limited as Internal Auditors.

Honasa Consumer Ltd's board, in its meeting on May 21, 2026, recommended a maiden final dividend of ₹3 per equity share (30% of face value of ₹10 each) for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The dividend, if declared, will be paid within 30 days from the AGM date. The board also approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.

Honasa Consumer Ltd reported audited financial results for the quarter and financial year ended March 31, 2026. Key highlights include a final dividend recommendation of ₹3 per equity share (30% of face value of ₹10 each), re-appointment of Mr. Subramaniam Somasundaram as an Independent Director, appointment of BDO India Services Private Limited as Internal Auditors, and designation of new Senior Management Personnel. The company's revenue from operations for FY26 stood at ₹23,054.12 million.